RenovoRx, Inc. (RNXT)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenues | 422 | 197 | ||
| Cost of revenues | 152 | 94 | ||
| Gross profit | 270 | 103 | ||
| Selling, general and administrative | 1,522 | 1,571 | ||
| Research and development | 1,426 | 1,642 | ||
| Total operating expenses | 2,948 | 3,213 | ||
| Loss from operations | -2,678 | -3,110 | ||
| Change in fair value of common warrant liability | - | -584 | ||
| Interest and dividend income | 133 | 106 | ||
| Change in fair value of common warrant liability | 350 | - | ||
| Total other (expense) income, net | -217 | 690 | ||
| Net loss | -2,895 | -2,420 | ||
| Net loss per share, basic | -0.08 | -0.08 | ||
| Net loss per share, diluted | -0.08 | -0.08 | ||
| Weighted-average shares of common stock outstanding, basic | 36,576,567 | 31,395,888 | ||
| Weighted-average shares of common stock outstanding, diluted | 36,576,567 | 31,395,888 | ||